Hepatitis B virus surface antigen and e antigen seroconversion in a known HBSS adolescent – Case report and review of the literature on treatment options and outcome

Hepatitis B virus (HBV) infection remains a global public health challenge with an estimated 257 million people in 2015 living as chronic carriers. Sub-Saharan Africa has the second largest burden of these carriers HBV infection. Children sickle cell anemia (HBSS) are prone to recurrent blood transfusion attendant risk blood-borne diseases including hepatitis There several studies Nigeria on prevalence viral children anemia. However, there is no report treatment HBSS infected HBV. This case describes 16-year-old known female adolescent who presented acute derangement liver function test, marked jaundice, and positive serology. Her DNA was remarkably high at 4,880,000 IU/ml monotherapy tenofovir, nucleoside analog led return enzymes normal values 3 months into treatment, seroconversion surface antigen (HBsAg) anti-HBs e-antigen (HBeAg) anti-HBe 12 24 patient maintained sustained virological response (undetectable HBV-DNA). Over years she functional cure, response, biochemical treatment. Nucleoside effective adolescents.